<DOC>
	<DOCNO>NCT02653417</DOCNO>
	<brief_summary>The purpose study determine clinical safety whether RAD1901 reduce frequency severity VMS postmenopausal woman regardless uterine status .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy RAD1901 Postmenopausal Women With Moderate Severe Vasomotor Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>To participate study , subject MUST : 1. postmenopausal woman 40 65 year age , inclusive 2. seek relief treatment moderate severe VMS 3. willing discontinue abstain follow : vaginal hormonal product ; transdermal oral estrogen estrogen/progestin combination ; progestin implant ; injectable estrogen ; topical progesterone cream , selective estrogen receptor modulators [ e.g. , ospemifene , raloxifene , tamoxifen , DuaveeÂ® ( conjugate estrogens bazedoxifene ) intrauterine device ( IUDs ) ] 4. normal clinically insignificant transvaginal ultrasound ( TVU ) 5. normal endometrial biopsy subsequent TVU without clinically relevant result 6. normal screen Papanicolaou ( Pap ) smear 7. mammogram within 9 month prior randomization . Subjects must Breast Imaging Reporting Data System ( BIRADS ) mammography result 1 2 enroll . Subjects follow characteristic eligible participate study : 1. history invasive breast cancer ductal carcinoma situ , melanoma gynecologic cancer . 2. use follow : oral estrogen , progestin , androgen , selective estrogen receptor modulator contain drug product within 8 week screen ( visit 1 ) transdermal hormone product within 4 week screen ( visit 1 ) vaginal hormone product ( ring , cream , gel ) within 4 week screen ( visit 1 ) progestin implants/injectables , IUDs estrogen pellets/injectables within 6 month screen ( visit 1 ) anabolic steroid 3. treat GnRH agonist within last year 4. treat antiestrogens , aromatase inhibitor within 2 month prior study entry 5. concurrently treat abstain gabapentin paroxetine serotonin norepinephrine reuptake inhibitor ( SNRIs ) VMS indication 3 month trial take within 4 week prior screen 6. endometrial biopsy baseline diagnosis gynecologic pathologist proliferative , hyperplasia , polyp cancer 7. unresolved finding suspicious malignancy breast examination</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>